Celanese Corporation Common Stock
CE
$0.00
-3.38%
Celanese Corporation is a global chemical company specializing in the production of acetic acid and specialty polymers. It is a leading player in the chemicals industry, leveraging its scale and technological expertise across diverse end markets.
CE
Celanese Corporation Common Stock
$0.00
Investment Opinion: Should I buy CE Today?
Based on a synthesis of the data, the objective assessment is a Hold. While analyst sentiment is positive (Buy consensus) and the stock shows strong momentum, the current price of $65.77 is already at the average analyst target of $65.25, offering limited near-term upside. This, combined with the substantial fundamental risks from high debt and volatile earnings, suggests waiting for a more attractive entry point or clearer signs of sustained profitability improvement would be prudent.
Sign up to view all
CE 12-Month Price Forecast
The risk-reward appears balanced. The compelling technical story is fully priced in, while fundamental repair is still in early stages. The high debt load necessitates caution.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celanese Corporation Common Stock's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
4 analysts
Implied Upside
—
vs. current price
Analyst Count
4
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analysts maintain a generally positive view, with a consensus recommendation of 'Buy' and a mean rating score of 1.94. The average target price from 16 analysts is $65.25, which is very close to the current stock price of $65.77. The target price range is wide, from a low of $41.00 to a high of $100.00, indicating divergent views on the company's future prospects.
Bulls vs Bears: CE Investment Factors
Celanese presents a high-risk, high-reward profile. Powerful technical momentum and a return to quarterly profitability are countered by severe balance sheet leverage and volatile fundamentals. The stock appears to be pricing in a recovery, leaving limited margin for error.
Bullish
- Strong Technical Momentum: Stock up 55.56% in 3 months, testing 52-week high of $67.82.
- Analyst Consensus Buy: 16 analysts rate Buy, average target $65.25 aligns with current price.
- Solid Free Cash Flow: Generated $803M TTM FCF, supporting financial flexibility.
- Return to Quarterly Profitability: Q4 2025 net income $19M vs. massive loss in Q3.
Bearish
- Extremely High Debt Load: Debt-to-equity ratio of 289.22 indicates significant leverage risk.
- Volatile and Declining Revenue: Q4 2025 revenue down 7% YoY, showing demand weakness.
- Poor Profitability Metrics: Negative ROE of -22.52% and trailing EPS of -$10.44.
- Cyclical Industry Exposure: Chemicals sector sensitive to economic cycles and input costs.
CE Technical Analysis
The stock has exhibited a strong and volatile uptrend over the observed period, with the price surging from a low near $35.53 in late November 2025 to a recent close of $65.77. This represents a significant recovery and breakout from the lower half of its 52-week range. Over the short term, the stock has shown exceptional strength, with a 1-month gain of 31.70% and a 3-month gain of 55.56%, dramatically outperforming the broader market as indicated by relative strength figures of 36.95 and 60.19, respectively. The current price of $65.77 is near the top of its 52-week range of $35.13 to $67.82, indicating the stock is testing recent highs after a powerful rally.
Beta
1.05
1.05x market volatility
Max Drawdown
-43.0%
Largest decline past year
52-Week Range
$35-$68
Price range past year
Annual Return
+14.1%
Cumulative gain past year
| Period | CE Return | S&P 500 |
|---|---|---|
| 1m | +27.8% | -3.7% |
| 3m | +50.3% | -4.1% |
| 6m | +40.8% | -2.1% |
| 1y | +14.1% | +16.1% |
| ytd | +50.7% | -3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CE Fundamental Analysis
Revenue and profitability have been highly volatile, with the latest Q4 2025 revenue of $2.20B showing a 7% year-over-year decline. Net income swung dramatically from a massive loss of -$1.36B in Q3 2025 to a modest profit of $19M in Q4 2025, reflecting significant one-time charges or impairments in the prior quarter. The company's financial health is characterized by a very high debt-to-equity ratio of 289.22, indicating a leveraged balance sheet, but it maintains a solid current ratio of 1.55 and generated strong free cash flow of $803M over the trailing twelve months. Operational efficiency metrics are mixed, with a negative Return on Equity (ROE) of -22.52% and a low Return on Assets (ROA) of 2.33%, suggesting challenges in generating profits from its capital base despite the recent quarterly return to profitability.
Quarterly Revenue
$2.2B
2025-12
Revenue YoY Growth
-0.07%
YoY Comparison
Gross Margin
+0.17%
Latest Quarter
Free Cash Flow
$803000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CE Overvalued?
Given the company's negative trailing twelve-month net income and EPS of -$10.44, the Price-to-Earnings (P/E) ratio is not meaningful. Therefore, the analysis focuses on the Price-to-Sales (P/S) ratio of 0.77 and the Enterprise Value-to-Sales (EV/Sales) ratio of 2.02. These sales-based multiples suggest the market is valuing the company's revenue stream at a moderate level relative to its market capitalization and enterprise value. Data for a direct peer comparison with industry averages is not available in the provided inputs.
PE
-4.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -74x~61x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
56.5x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is financial, stemming from an extremely high debt-to-equity ratio of 289.22, which makes the company vulnerable to rising interest rates and economic downturns. Operational risks include exposure to cyclical end markets like automotive and construction, evidenced by a 7% year-over-year revenue decline in Q4 2025, and poor capital efficiency shown by a negative Return on Equity. Market risks involve the stock's recent parabolic rise of over 55% in three months, bringing it near its 52-week high; this suggests the positive news may be fully priced in, increasing vulnerability to a correction if execution falters or macro conditions worsen.
FAQ
The paramount risk is financial leverage, with a debt-to-equity ratio of 289.22. Operational risks include exposure to economic cycles, shown by a 7% YoY revenue decline, and poor profitability metrics like a -22.52% ROE. Market risk includes the stock's 55% 3-month surge, which may have priced in the recovery.
The 12-month outlook is neutral with a base case target range of $60-$75 (55% probability), aligning with the analyst average. The bull case ($80-$100, 25% probability) depends on strong execution, while the bear case ($41-$52, 20% probability) aligns with the analyst low target and would be triggered by an economic downturn.
Based on sales multiples, CE does not appear overvalued, with a P/S ratio of 0.77. However, traditional P/E is negative due to trailing losses. The forward P/E of ~10.4 suggests the market expects earnings recovery. The stock is fairly valued relative to analyst targets, trading almost exactly at the $65.25 average.
At the current price of $65.77, CE is rated a Hold. It trades at the average analyst target price, suggesting limited near-term upside. While the technical momentum is strong, the high debt-to-equity ratio of 289 and volatile earnings history present significant risks that may outweigh the potential rewards at this valuation.
CE is more suitable for a tactical, medium-term investment based on cyclical recovery, not a core long-term hold. The high debt load creates long-term vulnerability. The powerful short-term momentum offers opportunity but requires active risk management due to the stock's volatility and proximity to its recent highs.